N,N-dimethyl-2-thiophen-2-ylethanamine;hydrochloride | 144235-89-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dimethyl-2-thiophen-2-ylethanamine;hydrochloride
• CAS: 144235-89-2
• 化学式: C8H14ClNS
• 分子量: 191.72
• InChiKey: WXLJRASEJDYXFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.27
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Echothiophate Iodide Process
  申请人：SHILPA MEDICARE LIMITED

  公开号：US20170002031A1

  公开（公告）日：2017-01-05

  The present invention relates to a process for preparation of Echothiophate Iodide (I). Echothiophate Iodide (I) obtained by the process of the present invention is obtained as new crystalline form designated as Form-SET. The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.

  本发明涉及一种制备碘化乙胆碱（I）的过程。通过本发明的方法获得的碘化乙胆碱（I）以新的晶体形式形式-SET命名。根据本发明的碘化乙胆碱（I）制备过程是一种环保的过程，避免使用有害的溶剂体系，并提供高纯度的碘化乙胆碱（I）。具有高纯度的碘化乙胆碱（I）晶体形式-SET的药物组合物在治疗青光眼等眼部疾病方面具有用处。
• Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
  申请人：Malecha W. James

  公开号：US20070027184A1

  公开（公告）日：2007-02-01

  Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

  本文披露了如下所述的Formula VII的磺胺类化合物。本文还披露了用于治疗疾病状态的方法和组合物，包括但不限于癌症、自身免疫疾病、组织损伤、中枢神经系统疾病、神经退行性疾病、纤维化、骨疾病、多聚谷氨酰胺重复疾病、贫血、地中海贫血、炎症症状、心血管疾病以及血管生成在发病机制中起作用的疾病，使用本发明的化合物。此外，还披露了调节组蛋白去乙酰化酶（HDAC）活性的方法。
• [EN] SILYL MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] MONOMÈRES SILYLES APTES À FORMER UN MULTIMÈRE DANS UNE SOLUTION AQUEUSE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV CORNELL

  公开号：WO2013058825A1

  公开（公告）日：2013-04-25

  Described herein are silyl monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. Such multimer forming associations of monomers may be promoted by the proximal binding of the monomers to their target biomolecule(s). In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本文描述了一些硅基单体，当它们与一个、两个、三个或更多的其他单体在水介质中接触时，能够形成生物学上有用的多聚体。这种单体的多聚体形成关联可以通过单体与其目标生物分子的近距离结合来促进。在一个方面，这种单体可以在水介质中（例如在体内）与另一个单体结合形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团和连接元素的连接器元素。在水介质中，这些考虑到的单体可以通过每个连接元素连接在一起，因此可以同时调节一个或多个生物分子，例如调节蛋白质上的两个或更多的结合域或不同蛋白质上的结合域。
• [EN] ECHOTHIOPHATE IODIDE PROCESS<br/>[FR] PROCÉDÉ D'IODURE D'ÉCHOTHIOPATE
  申请人：SHILPA MEDICARE LTD

  公开号：WO2015114470A1

  公开（公告）日：2015-08-06

  The present invention relates to a process for preparation of Echothiophate Iodide Echothiophate Iodide (I) obtained by the process of the present invention is obtained as crystalline form designated as Form-SET. (I) The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.

  本发明涉及一种制备Echothiophate Iodide的方法。根据本发明的方法获得的Echothiophate Iodide（I）以结晶形式形成，被指定为Form-SET。本发明的Echothiophate Iodide（I）制备方法是一种环保的方法，避免使用有害的溶剂体系，并提供高纯度的Echothiophate Iodide（I）。所述结晶Form-SET的高纯度Echothiophate Iodide（I）制药组合物在治疗青光眼等眼部疾病方面非常有用。
• SILYL MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
  申请人：Barany Francis

  公开号：US20140163229A1

  公开（公告）日：2014-06-12

  Described herein are silyl monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. Such multimer forming associations of monomers may be promoted by the proximal binding of the monomers to their target biomolecule(s). In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本文描述了一些硅基单体，这些单体能够在水介质中与其他单体接触时形成生物上有用的多聚体。这种多聚体形成的单体关联可以通过单体与其目标生物分子的近距离结合来促进。在一个方面，这样的单体可以在水介质（例如体内）中与另一个单体结合形成多聚体（例如二聚体）。考虑的单体可能包括配体部分、连接元素和连接配体部分和连接元素的连接器元素。在水介质中，这样的单体可以通过每个连接器元素连接在一起，因此可以同时调节一个或多个生物分子，例如调节蛋白质上的两个或更多结合域或不同蛋白质上的结合域。